4//SEC Filing
DeLong Mark Jeffrey 4
Accession 0001127602-25-017275
CIK 0001492422other
Filed
Jun 10, 8:00 PM ET
Accepted
Jun 11, 4:10 PM ET
Size
5.2 KB
Accession
0001127602-25-017275
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-06-09$19.39/sh+82,500$1,599,675→ 82,500 totalExercise: $19.39Exp: 2035-06-09→ Common Stock (82,500 underlying)
Footnotes (1)
- [F1]This represents stock option award granted on June 9, 2025, which will vest over a two-year period. Specifically, 50% of the options will vest on each of the one-year and two-year anniversaries of the grant date, contingent upon continued service.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001856078
Filing Metadata
- Form type
- 4
- Filed
- Jun 10, 8:00 PM ET
- Accepted
- Jun 11, 4:10 PM ET
- Size
- 5.2 KB